Humanitarian Horizons: Christina DiArcangelo Unveiled

Cannabis Research & Patient Advocacy: A Conversation with Erik Asher

May 03, 2024 Christina DiArcangelo Season 2 Episode 12
Cannabis Research & Patient Advocacy: A Conversation with Erik Asher
Humanitarian Horizons: Christina DiArcangelo Unveiled
More Info
Humanitarian Horizons: Christina DiArcangelo Unveiled
Cannabis Research & Patient Advocacy: A Conversation with Erik Asher
May 03, 2024 Season 2 Episode 12
Christina DiArcangelo


In this episode of Humanitarian Horizons, Christina DiArcangelo welcomes Erik Asher, a dear friend and fellow advocate in the cannabinoid space. They delve into the changes they've witnessed in Pennsylvania's medical cannabis program and how it has impacted patients. Despite promises of a patient-centric approach, the program's evolution has been met with mixed results. Initially, the program boasted high-quality products from numerous small companies focused on patient well-being. However, the entry of out-of-state companies led to consolidation, dwindling product variety, and increased prices.

 

They reflect on the program's early days when it held promise for clinical research collaborations with prestigious universities. Erik emphasizes the importance of this research for advancing medical understanding and product development. Yet, despite these potential benefits, they highlight ongoing challenges and discrimination faced by those advocating for cannabis as a legitimate medicine. Throughout the conversation, they stress the need for continued advocacy to ensure patient access, rights, and dignity in the evolving landscape of medical cannabis.

Show Notes


In this episode of Humanitarian Horizons, Christina DiArcangelo welcomes Erik Asher, a dear friend and fellow advocate in the cannabinoid space. They delve into the changes they've witnessed in Pennsylvania's medical cannabis program and how it has impacted patients. Despite promises of a patient-centric approach, the program's evolution has been met with mixed results. Initially, the program boasted high-quality products from numerous small companies focused on patient well-being. However, the entry of out-of-state companies led to consolidation, dwindling product variety, and increased prices.

 

They reflect on the program's early days when it held promise for clinical research collaborations with prestigious universities. Erik emphasizes the importance of this research for advancing medical understanding and product development. Yet, despite these potential benefits, they highlight ongoing challenges and discrimination faced by those advocating for cannabis as a legitimate medicine. Throughout the conversation, they stress the need for continued advocacy to ensure patient access, rights, and dignity in the evolving landscape of medical cannabis.